Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.

Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 2015 Mar 24; 10(11):1850-60.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.